NETRAMARK HOLDINGS INC.

Ajouter à une liste

Communiqués NetraMark Holdings Inc. OTC Markets

Actions

AINMF

CA64119M1059

Logiciels

Marché Fermé - OTC Markets Autres places de cotation 17:09:27 15/06/2026			Varia. 5j.	Varia. 1 janv.
0,5530 ^USD	-10,98%		-10,98%	-30,46%

14/05	NetraMark Holdings Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 31 mars 2026	CI
07/05	NetraMark Holdings Inc. annonce la démission de Lawrence Guy de son poste d'administrateur, effective au 7 mai 2026	CI

Communiqués

09/06	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
25/05	Upcoming Meeting Dates - May 25, 2026	NE
20/05	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
14/05	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
07/05	NetraMark Announces Change To Board Of Directors	AQ
05/05	NetraMark Holdings Inc. (AIAI) ouvre les marchés	NE
05/05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE
04/05	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI	AQ
30/04	NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026	AQ
22/04	NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	AQ
20/04	Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development	AQ
09/04	Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain	AQ
25/03	NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset	AQ
19/03	NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference	AQ
11/03	NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

DERNIÈRES HEURES | -40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !

PROFITEZ-EN MAINTENANT

×